{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The overall study was terminated early. The AML Dose Escalation cohort and the DLBCL Expansion Part A cohort were terminated early due to enrollment challenges. The anti-CD38 mAb-refractory RRMM cohort and the R/R AML cohort in Expansion Part A were not opened."},"pointOfContact":{"email":"clinicaltrials@genmab.com","organization":"Genmab","phone":"+45 7020 2728","title":"CLINICAL TRIAL INFORMATION"}}